Biliverdin (technical grade)
(Synonyms: 去氫膽紅素) 目录号 : GC49708
A bile pigment
Cas No.:114-25-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >70.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Biliverdin is a porphyrin bile pigment and precursor in the biosynthesis of bilirubin .1,2 It is formed via oxidative catabolism of heme by heme oxygenase-1 (HO-1) and further reduced to bilirubin by biliverdin reductase. Biliverdin has antioxidant activity in oxygen radical absorbance capacity (ORAC) and Trolox equivalent absorbance capacity (TEAC) assays when used at concentrations greater than 0.5 µM.3
1.Liu, Y., MoËnne-Loccoz, P., Loehr, T.M., et al.Heme oxygenase-1, intermediates in verdoheme formation and the requirement for reduction equivalentsJ. Biol. Chem.272(11)6909-6917(1997) 2.Maines, M.D.The heme oxygenase system: A regulator of second messenger gasesAnnu. Rev. Pharmacol. Toxicol.37517-554(1997) 3.MÖlzer, C., Huber, H., Steyrer, A., et al.In vitro antioxidant capacity and antigenotoxic properties of protoporphyrin and structurally related tetrapyrrolesFree Radic. Res.46(11)1369-1377(2012)
| Cas No. | 114-25-0 | SDF | Download SDF |
| 别名 | 去氫膽紅素 | ||
| Canonical SMILES | OC(CCC1=C(/C=C2C(CCC(O)=O)=C(C)C(/C=C3NC(C(C=C)=C\3C)=O)=N/2)NC(/C=C4NC(C(C)=C\4C=C)=O)=C1C)=O | ||
| 分子式 | C33H34N4O6 | 分子量 | 582.7 |
| 溶解度 | DMSO : 3 mg/mL (5.15 mM; Need ultrasonic and warming) | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7161 mL | 8.5807 mL | 17.1615 mL |
| 5 mM | 0.3432 mL | 1.7161 mL | 3.4323 mL |
| 10 mM | 0.1716 mL | 0.8581 mL | 1.7161 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Oxidant and anti-oxidant status in common brain tumors: Correlation to TP53 and human Biliverdin reductase
Clin Neurol Neurosurg 2017 Jul;158:72-76.PMID:28499219DOI:10.1016/j.clineuro.2017.05.003.
Objective: To assess oxidant and antioxidant status in patients with common brain tumors; namely meningiomas, low-grade gliomas (LGG) and high-grade gliomas (HGG) and to compare with normal brain tissues. Patients and methods: Almost nine biomarkers were measured in 59 brain tumors obtained during surgery and 15 normal brain tissues that were collected during autopsy. Results were compared between two groups. Results: In general, protein oxidation and lipid peroxidation increased while antioxidant capacity decreased significantly in tumors compared to the controls (p<0.05) and higher the grade of the tumor, higher the levels of oxidation and lower the anti-oxidation. Conclusions: Reactive oxygen species may play a crucial role in the pathogenesis of these common brain tumors. As the processes at the molecular level understood, targeted-treatment adjunct to surgical removal will be possible to cope with these devastating brain tumors.
Cyclobilirubin formation by in vitro photoirradiation with neonatal phototherapy light
Pediatr Int 2001 Jun;43(3):270-5.PMID:11380923DOI:10.1046/j.1442-200x.2001.01398.x.
Background: The main mechanism of phototherapy for neonatal hyperbilirubinemia is the production and excretion of (EZ)- and (EE)-cyclobilirubin (4E,15Z- and 4E,15E-cyclobilirubin). Thus, the clinical efficacy of the light source for phototherapy must be evaluated by cyclobilirubin formation from (ZZ)-bilirubin in in vitro photoirradiation. Methods: In the present study, we investigated the in vitro production pattern of bilirubin photoisomers by phototherapy light from the bilirubin-human serum albumin complex. Results: No clear difference was found in the curves relative to (ZZ)-bilirubin and its photoisomers under aerobic and anaerobic conditions. The ratio of (EZ)-cyclobilirubin to (ZZ)-bilirubin increased proportionately to the dose of irradiating light and no photoequilibrium state was observed analogous to that found in configurational photoisomerization. The concentration of (EZ)- and (EE)-cyclobilirubin increased proportionately with the grade of the percentage decrease in A(460 nm) from 0 to 23%. With a percentage decrease in A(460 nm) of 23% or more, the cyclobilirubin concentrations reached a steady state. The reason for this appears to be that the concentration of (ZZ)-bilirubin, a substrate for photoisomers, dropped below 1 mg/100 mL. Biliverdin was produced only in trace amounts. However, the absorption at 520--700 nm increased after a percentage decrease in A(460 nm) of more than 23%. Conclusions: The results of the present study show that little bilirubin photooxidation occurred with in vitro aerobic photoirradiation. Before the concentration of cyclobilirubin reaches a steady state, it is theoretically valid to use the percentage decrease in A(460 nm) for the evaluation of the clinical efficacy of the light source.